U.S. widens tariff reach
The U.S. has broadened its national‑security tariff powers to cover not only steel and aluminium but also copper and patented pharmaceutical products — a notable move because tariffs on high‑value drugs touch innovation‑heavy supply chains. (mondaq.com). That shift sits awkwardly alongside a large deregulatory push—analysts say hundreds of rollbacks are being muted or complicated by new trade unpredictability. (washingtontimes.com). Meanwhile, market‑integrity questions have surfaced after reports that unusual options trades preceded past tariff announcements, underscoring the risk of policy shocks feeding into trading behavior. (investing.com)
The White House just stretched a national-security trade tool far beyond rebar and soda cans. Orders issued on April 2 rewrote Section 232 tariffs for steel, aluminum, and copper, and opened a separate Section 232 track for patented pharmaceutical products. (whitehouse.gov) Section 232 is a 1962 law that lets a president restrict imports after a national-security finding by the Commerce Department. It was built for cases where Washington thinks foreign supply could leave the country short of critical goods in a crisis. (nortonrosefulbright.com) For metals, the change was not just “higher tariffs.” The April 2 proclamation shifted covered steel, aluminum, and copper goods to a new structure that, from April 6, applies duties to the full customs value of many covered imports instead of only the metal content. (ey.com) That sounds technical until you picture a transformer, a cable spool, or a machine part with copper inside it. Under the new setup, importers can get hit on the value of the whole product, which trade lawyers say changes the math for manufacturers that buy finished components rather than raw metal. (natlawreview.com) The White House says the top rate on primary steel, aluminum, and copper articles is 50%, with lower tiers for some derivative products and special treatment for some goods tied to the electrical grid. The administration says the point is to protect domestic capacity in industries it now treats as strategic. (whitehouse.gov) Copper is the quiet part of this story. It sits inside power lines, data centers, electric motors, and weapons systems, so adding it to the same national-security tariff architecture as steel and aluminum pulls a much bigger slice of industrial supply chains into tariff risk. (constructiondive.com) The pharmaceutical piece is even more unusual because patented drugs are not bulk commodities. They are high-margin products built on global chains of ingredients, contract manufacturing, and intellectual property, so a tariff there lands closer to research labs and branded medicine portfolios than to blast furnaces. (nortonrosefulbright.com) That creates a collision inside the administration’s own economic message. The Office of Management and Budget says agencies logged 646 deregulatory actions against 5 regulatory actions, but analysts argue the savings from those rollbacks are harder for companies to bank when tariff rules can abruptly change input costs, sourcing plans, and pricing. (whitehouse.gov, grabien.com) Outside analysts are already disputing the deregulatory scoreboard itself. The George Washington University Regulatory Studies Center says the 129-to-1 ratio counts a wide range of deregulatory moves in the numerator but only significant regulatory actions in the denominator, which makes the headline look bigger than the underlying comparison. (regulatorystudies.columbian.gwu.edu) Markets are reacting to the tariff regime as a source of sudden policy shocks, not as a slow-moving trade backdrop. Reuters reported that unusual options activity appeared ahead of major Trump tariff announcements, including a tariff pause that sent the Standard and Poor’s 500 index up 9.5% after a 1:18 p.m. social-media post on April 9. (energynow.com, usnews.com) That is why this move reaches past customs brokers and metal buyers. Once Section 232 can swing from steel and aluminum into copper and patented pharmaceuticals, trade policy stops looking like a border tax on a few old-line industries and starts looking like a live variable in factories, drug pricing, and even options markets. (mondaq.com, investmentnews.com)
